Acoramidis Therapy Increases Serum TTR Levels in ATTR-CM

A new study presented at ACC.25 shows that acoramidis therapy induces a significant increase in serum transthyretin (sTTR), which is typically lower in patients with variant TTR amyloid cardiomyopathy (ATTRv-CM).

The investigators noted that all outcomes were analyzed using a stratified Cox proportional hazard model.

The findings showed that at baseline, sTTR was lower in individuals with ATTRv-CM than in patients with wild-type TTR amyloid cardiomyopathy (ATTRwt-CM). After acoramidis therapy, the study found that patients with ATTRv-CM had greater increases in sTTR, yet achieved sTTR levels similar to those of patients with ATTRwt-CM. The investigators further noted that this increase was stable through month 30. Overall, in a prespecified subgroup analysis of time to all-cause mortality or cardiovascular-related hospitalization, the findings of the Cox-proportional hazard model were observed to be statistically significant in both patients with ATTRv-CM (hazard ratio [HR], 0.41; 95% CI, 0.21-0.81) and those with ATTRwt-CM (HR, 0.69;  95% CI, 0.52-0.90).

“Despite greater TTR destabilization and lower baseline sTTR in ATTRv-CM pts, acoramidis treatment induced a greater proportional increase in sTTR and achieved similar absolute sTTR levels as ATTRwt-CM patients. In a pre-specified analysis, this resulted in statistically significant better outcomes in both ATTRv-CM and ATTRwt-CM patients,” the investigators concluded.

Reference

Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy. Abstract presented at: ACC25 [American College of Cardiology meeting, 2025]. March 29-31, 2025; Chicago, IL.